pepinemab,nivolumab,ipilimumab
vaccinex,bms
['pepinemab', 'nivo', 'biomarker', 'ipilimumab', 'nivolumab', 'melanoma', 'marker ', 'vaccinex']
tomorrow at 9:15 am cest, 's dr. michael lowe, with vaccinex co-authors, will present data from our integrated biomarker trial of pepinemab with ipilimumab and/or nivolumab in resectable stage iii melanoma, at #esmo22. 
Clinical stage #biotech company engaged in the development of novel therapeutic #antibodies for #neurodegenerative disorders and #oncology.